Table of Contents
Volume 2011, Article ID 439425, 6 pages
Clinical Study

Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

1Department of Public Health and Infectious Diseases, Sapienza, University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
2Department of Oral and Maxillofacial Sciences, Sapienza, University of Rome, Viale Regina Elena, 287/A, 00161 Rome, Italy

Received 15 October 2010; Revised 22 February 2011; Accepted 13 March 2011

Academic Editor: Shingo Tsuji

Copyright © 2011 Vito Trinchieri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recurrent aphthous stomatitis is a common disorder of the oral cavity, affecting mainly young people. It is characterized by small ulcers which can be very painful and generally heal spontaneously within 7–14 days. There is currently no therapy that can provide rapid healing. This study evaluated the efficacy and rapidity of response of a lozenge containing Lactobacillus brevis CD2. 30 patients were randomized to take 4 lozenges a day of active product or placebo for 7 days. Signs and symptoms as well as laboratory parameters in the saliva were assessed at the start of the study and after 7 days of treatment. The study demonstrated the efficacy and the rapidity of response of the Lactobacillus brevis CD2 lozenges in resolving the clinical signs and symptoms of aphthous stomatitis, with a significantly rapid improvement of pain. This is the first study confirming the efficacy of a probiotic product in this pathology.